m701
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 30, 2018 (NCT04501744)
Timeline
Indications
Mechanism of action
- Epithelial cell adhesion moleculeINHIBITOR
EPCAM inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06432296 | Phase 3 | Mar 20, 2024 | Harbin Medical University, People's Liberation Army of China, Wuhan YZY Biopharma Co., Ltd. |
| NCT05543330 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2022 | Chinese Academy of Medical Sciences, Wuhan YZY Biopharma Co., Ltd. |
| NCT06266091 | Phase 2 | Nov 24, 2021 | People's Liberation Army of China, Wuhan YZY Biopharma Co., Ltd. |
| NCT04501744 | Phase 1 | Oct 30, 2018 | Huazhong University of Science and Technology, People's Liberation Army of China, Wuhan YZY Biopharma Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Wuhan YZY Biopharma Co., Ltd. | For profit | 4 | 4 | 3 | 2018 |
| People's Liberation Army of China | Government | 3 | 0 | 3 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1